Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial

OBJECTIVE: This study evaluated the safety and preliminary efficacy of vorolanib, a novel tyrosine kinase inhibitor, for treatment of patients with advanced solid tumors. METHODS: During dose escalation, patients received increasing doses of oral vorolanib (50−250 mg once daily) in cycles of four we...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Chin J Cancer Res
Main Authors: Song, Yan, Wang, Jinwan, Ren, Xiubao, Jin, Jie, Mao, Li, Liang, Chris, Ding, Lieming, Yang, Lin
Formáid: Artigo
Teanga:Inglês
Foilsithe: AME Publishing Company 2021
Ábhair:
Original Article
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7941683/
https://ncbi.nlm.nih.gov/pubmed/33707933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21147/j.issn.1000-9604.2021.01.11
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla